Isoniazid

證據等級: L5

預測適應症: 1 個

Isoniazid: From Tuberculosis to Conjunctivitis

One-Sentence Summary

Isoniazid is a first-line antituberculosis agent, historically used to treat tuberculosis infection. The TxGNN model predicts it may be effective for Conjunctivitis, with 1 clinical trial (not directly relevant to conjunctivitis) and 20 publications (mostly case reports and reviews of TB-related ocular disease) associated with this direction — the evidence itself is assessed as weak and likely confounded.

Quick Overview

Item	Content
Original Indication	Tuberculosis (isoniazid is a well-established first-line antituberculous agent; formal regulatory label text is not available in this evidence pack)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.36%
Evidence Level	L5
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for isoniazid is not available in this evidence pack. Based on known information, isoniazid inhibits mycolic acid synthesis in Mycobacterium tuberculosis, and its efficacy in tuberculosis treatment is well established.

However, the link between isoniazid and conjunctivitis appears to be an artifact of the underlying knowledge graph rather than a genuine pharmacological signal. Three confounded relationships likely drive the high TxGNN score: (1) conjunctivitis can itself be an ocular manifestation of active tuberculosis infection, so isoniazid treats the causative mycobacterial infection rather than conjunctival inflammation as an independent indication; (2) isoniazid has documented ocular toxicity (e.g., optic neuritis), and several of the retrieved case reports describe adverse ocular reactions rather than therapeutic benefit; (3) isoniazid is used to treat mycobacterial infection following intravesical BCG instillation, where a reactive arthritis–conjunctivitis syndrome can occur as a complication — again treating the underlying mycobacterial trigger, not acting mechanistically on conjunctival inflammation itself.

One partial exception is phlyctenular keratoconjunctivitis, a delayed-hypersensitivity reaction to tuberculoprotein, for which isoniazid prophylaxis has actually been studied (PMID 14253168, 1965). This represents a plausible, TB-specific mechanistic link, but it does not generalize to conjunctivitis as a broad indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04094012	Phase 3	Completed	490	Compared systemic adverse drug reaction rates between 3HP (rifapentine + isoniazid) and 1HP regimens for latent TB infection; primary endpoint was systemic reactions, with no direct relevance to conjunctivitis efficacy or safety (relevance grade C — largely unrelated)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14253168	1965	Prophylaxis study	The American Review of Respiratory Disease	Isoniazid prophylaxis studied in phlyctenular keratoconjunctivitis among Alaskan populations with high TB prevalence
5103251	1971	Case series	Annales d'oculistique	Local (topical) use of isoniazid in treatment of ocular tuberculosis
10641112	1999	Case series	Oftalmologia	28 cases of tuberculous keratoconjunctivitis, mostly children with primary TB and positive tuberculin skin tests
25433746	2014	Case report	Canadian Journal of Ophthalmology	Conjunctival phlyctenulosis re-emphasized as a presenting sign of impending clinical tuberculosis
33607832	2021	Case report	Medicine	Pediatric case of primary sinonasal tuberculosis presenting with phlyctenular keratoconjunctivitis
26692731	2015	Case report	Middle East African Journal of Ophthalmology	Tuberculous conjunctivitis in an anophthalmic socket following prior TB infection
17133069	2006	Case report	Cornea	Mycobacterium tuberculosis presenting as chronic red eye / conjunctival TB
14089390	1964	Case report	Archives of Ophthalmology	Primary tuberculosis of the conjunctiva
1363080	1992	Review	Optometry Clinics	Review of ocular side effects of systemic drugs; notes conjunctivitis/blepharoconjunctivitis associated with several drug classes
12226788	2002	Case report	Deutsche Medizinische Wochenschrift	Chronic reactive arthritis with conjunctivitis after intravesical BCG therapy; isoniazid used to treat underlying mycobacterial complication

New Zealand Market Information

Isoniazid is currently not marketed in New Zealand, and no authorization records are available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted association between isoniazid and conjunctivitis is not supported by a direct pharmacological mechanism. The retrieved clinical trial is unrelated, and nearly all literature reflects confounded relationships — conjunctivitis as a manifestation of TB infection, isoniazid-related ocular toxicity, or treatment of a mycobacterial trigger rather than conjunctivitis itself. Combined with L5 evidence level and no New Zealand market presence, the evidence does not support progression at this time.

To proceed, the following is needed:

Isoniazid MOA and TFDA/regulatory label data (currently flagged as Blocking/High data gaps)
A dedicated mechanistic or preclinical study on isoniazid's direct anti-inflammatory or antimicrobial effect on non-tuberculous conjunctivitis
Clarification of whether the intended indication is conjunctivitis broadly or specifically TB-associated phlyctenular keratoconjunctivitis (the one subtype with plausible rationale)
Safety and DDI data, currently unavailable (query status: not found)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.